Explore

Trendline Trendline
Roche Invests $1 Billion in C4T's Degrader-Antibody Conjugates

Roche Invests $1 Billion in C4T's Degrader-Antibody Conjugates

Roche Invests $1 Billion in C4T's Degrader-Antibody Conjugates
Trendline Trendline
Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development

Roche Expands Partnership with C4 Therapeutics, Commits Over $1 Billion for Cancer Therapy Development
Trendline Trendline
Biotechnology and Pharmaceutical Services Outsourcing Market Projected to Reach USD 89.82 Billion by 2035

Biotechnology and Pharmaceutical Services Outsourcing Market Projected to Reach USD 89.82 Billion by 2035

Biotechnology and Pharmaceutical Services Outsourcing Market Projected to Reach USD 89.82 Billion by 2035
Trendline Trendline
Merck Co. Expands Hematology Portfolio with $6.7 Billion Acquisition of Terns Pharmaceuticals

Merck Co. Expands Hematology Portfolio with $6.7 Billion Acquisition of Terns Pharmaceuticals

Merck Co. Expands Hematology Portfolio with $6.7 Billion Acquisition of Terns Pharmaceuticals
Trendline Trendline
Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition

Gilead Sciences Expands Oncology Portfolio with $5 Billion Tubulis Acquisition
Trendline Trendline
Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities

Gilead Sciences Acquires Tubulis for $5 Billion to Enhance Cancer Treatment Capabilities
Trendline Trendline
Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology

Gilead Sciences Acquires Tubulis to Enhance Oncology Pipeline with Advanced ADC Technology
Trendline Trendline
Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead to Acquire Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Trendline Trendline
Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions

Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions

Oncology Drug Development: Streamlined Preclinical Toxicology for Faster IND Submissions
Trendline Trendline
AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials

AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials

AI in Life Sciences Market Projected to Transform Drug Development and Clinical Trials
Trendline Trendline
Eli Lilly's Foundayo Approval Sparks Competition with Novo Nordisk Amid Pharma Industry Changes

Eli Lilly's Foundayo Approval Sparks Competition with Novo Nordisk Amid Pharma Industry Changes

Eli Lilly's Foundayo Approval Sparks Competition with Novo Nordisk Amid Pharma Industry Changes
Trendline Trendline
Oncology Drug Development: Streamlining Preclinical to Clinical Safety Pathways

Oncology Drug Development: Streamlining Preclinical to Clinical Safety Pathways

Oncology Drug Development: Streamlining Preclinical to Clinical Safety Pathways